Short-term effect on growth of two doses of GRF 1-44 in children with growth hormone deficiency: comparison with growth induced by methionyl-GH administration

Horm Res. 1987;27(4):181-9. doi: 10.1159/000180817.

Abstract

In a double-blind study 12 prepubertal children with idiopathic growth hormone (GH) deficiency were treated with growth hormone releasing factor (GRF) 1-44 in a dosage of 7.5 or 15 micrograms/kg body weight, administered once a day subcutaneously. With 7.5 micrograms/kg the average growth velocity increased from 2.5 to 4.6 cm/year, an insufficient response. With the higher dosage the average growth velocity increased from 2.7 to 7.0 cm/year, a similar increase as observed with GH therapy in subsequent periods. In 3 of the 6 children treated with the higher dose appropriate catch-up growth was observed. The growth response of the lower leg length was not always consistent with the statural growth response.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Body Height
  • Child
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Growth Disorders / drug therapy*
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / deficiency*
  • Growth Hormone / therapeutic use
  • Growth Hormone-Releasing Hormone / therapeutic use*
  • Hormones / therapeutic use*
  • Human Growth Hormone
  • Humans
  • Male

Substances

  • Hormones
  • Human Growth Hormone
  • Growth Hormone
  • Growth Hormone-Releasing Hormone